Catabasis Pharmaceuticals to Present at Upcoming Investor and Industry Conferences
News Mar 29, 2012
-- Needham & Company’s 11th Annual Healthcare Conference, being held April 3-4 at the New York Palace Hotel in New York City. Dr. Jirousek will give a company presentation at 3:40 p.m. on Tuesday, April 3. This conference is a high-impact forum for institutional investors and venture capital firms to hear the latest updates from senior management teams of both public and private companies in sectors such as biotechnology, specialty pharmaceuticals, diagnostics and medical technology.
-- 2nd Diabetes Summit, being held April 19-20 at the Hyatt Harborside in Boston. Dr. Jirousek will present an overview of CAT-1004 as a novel new chemical entity for treating type 2 diabetes in the session “Clinical Drug Development in Diabetes” at 4:05 p.m. on Thursday, April 19. This conference will bring together the leading experts on diabetes from both industry and academia to discuss novel targets for diabetes, lessons to learn from current clinical drug development, and business strategies and opportunities under the current regulatory landscape.
-- Future Leaders in the Biotech Industry, being held April 20 at the Millennium Broadway Hotel & Conference Center in New York City. Dr. Jirousek will give a presentation on Catabasis’ novel approach to drug development at 3 p.m. The presentation will feature an overview of the company, proprietary chemistry platform and promising pipeline, including CAT-1004. This conference will showcase companies best positioned to provide market leadership and will continue to emphasize fresh investment opportunities.
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
BioAscent Announces New CEO and Plans to Expand Discovery Services OfferingNews
BioAscent Discovery Limited appoints new CEO, Paul Smith in preparation for the expansion of companies discovery services.READ MORE
Potential Barcode Identified for a Form of Alcoholic Liver DiseaseNews
NIAAA-supported researchers have discovered that extracellular vesicles released by liver cells in a mouse model of alcoholic steatohepatitis contain a miRNA signature detectable in the blood.READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018